Designing Cardiovascular Outcomes Trials in Clonal Hematopoiesis of Indeterminate Potential

Clonal hematopoiesis of indeterminate potential (CHIP) has emerged as an independent and potent cardiovascular risk factor. As genetic sequencing becomes more widespread and the population ages, the identification of CHIP will increase substantially. Despite strong epidemiologic and mechanistic evidence linking CHIP to cardiovascular disease, no randomized trials have prospectively addressed this population.

To examine the major challenges in designing cardiovascular outcomes trials in CHIP and to propose a road map for advancing the evidence base for potential CHIP-targeted therapies.

This Special Communication synthesizes current epidemiologic, mechanistic, and clinical considerations relevant to cardiovascular trial design in CHIP.

Multiple challenges complicate the design of cardiovascular outcomes trials in CHIP. Genetic heterogeneity across CHIP driver mutations leads to distinct biological mechanisms and cardiovascular outcomes, complicating end point selection. Cardiovascular risk also varies by clone size, creating trade-offs between broad eligibility and adequate event rates and statistical power. Differences in sequencing platforms and detection thresholds further hinder consistent risk stratification and reproducibility. Moreover, limited access to genetic testing impedes timely identification and enrollment of eligible participants. Finally, ethical concerns related to screening asymptomatic individuals, along with the advanced age and comorbidity burden of many CHIP carriers, pose challenges to recruitment, retention, and trial feasibility.

Designing cardiovascular outcomes trials in CHIP will require moving beyond a 1-size-fits-all approach toward genotype-informed, mechanism-driven trial frameworks. Leveraging innovative trial designs, integrating CHIP analyses into ongoing cardiovascular trials, and fostering interdisciplinary multicenter collaboration will accelerate translating CHIP biology into effective cardiovascular therapies. Establishing an evidence base for managing CHIP-associated cardiovascular risk represents a critical and timely priority for precision cardiovascular medicine.